Epstein-Barr Virus, or EBV, is one of the most common human viruses in the world; almost 95% of 35-40 year olds in the United States have been infected at some point in their life. The Epstein-Barr Virus can be contracted any time after an infant loses its maternal antibody protection. The virus can cause infectious mononucleosis in children, teens, and young adults, but some adolescents and most adults who contract the virus only experience a mild illness. After the initial infection, the Epstein-Barr Virus remains dormant in saliva and blood cells, as well as in the immune system. The virus has no cure or containment strategy, because it is transferred through saliva, even when the individual with the virus appears healthy. The newly infected individual may not show symptoms for 4 to 6 weeks, so the virus spreads easily and is difficult to contain. Epstein-Barr Virus has been linked to a few cancers, and a vaccine is currently being developed.
Epstein-barr Virus Infections Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Epstein-barr Virus Infections below!
For more information on how to use Laverne, please read the How to Guide.
We have 5538 products for the study of Epstein-barr Virus Infections that can be applied to Chromatin Immunoprecipitation, Western Blot, Flow Cytometry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry, Chromatin Immunoprecipitation (ChIP) from our catalog of antibodies and ELISA kits.
Epstein-barr Virus Infections is also known as Epstein-barr Viral Infections, Epstein-barr Virus Disease, Epstein-barr Virus Infection, Infections, Ebv, Infections, Epstein-barr Virus.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.